March 19, 2023
2 min learn
Supply/Disclosures
Printed by:
Kwatra SG, et al. Nemolizumab monotherapy improved itch, pores and skin lesions and sleep disturbance in sufferers with prurigo nodularis: Outcomes from a part 3 trial (OLYMPIA 2). Introduced at: American Academy of Dermatology Annual Assembly; March 17-21, 2023; New Orleans.
Disclosures:
Kwatra reviews being an advisory board member, marketing consultant and/or investigator for AbbVie, Amgen, Arcutis Biotherapeutics, Asian Prescribed drugs, Cara Therapeutics, Fortress Biosciences, Celldex Therapeutics, Galderma, Genzada Prescribed drugs, Incyte Corp., Johnson & Johnson, LEO Pharma, Novartis Prescribed drugs Corp., Pfizer, Regeneron Prescribed drugs and Sanofi.
Key takeaways:
- Sufferers with prurigo nodularis confirmed important enhancements in itch, sleep disturbance and lesions after nemolizumab therapy.
- Nemolizumab is an interleukin-31 receptor alpha antagonist.
NEW ORLEANS — Signs of prurigo nodularis have been considerably improved after 16 weeks of monotherapy with nemolizumab, in keeping with a presenter on the American Academy of Dermatology Annual Assembly.
“Prurigo nodularis, PN, is characterised by these intensely itchy nodules which are generally on the extremities and the trunk,” Shawn G. Kwatra, MD, affiliate professor of dermatology at Johns Hopkins College Faculty of Drugs and director of the Johns Hopkins Itch Heart, mentioned throughout his presentation. “By way of pathophysiology, we imagine it is a neuroimmune mediated pores and skin illness, and it truly additionally has inducement of not solely sort 2 irritation but additionally parts of sort 17 and kind 22 irritation.
Nemolizumab is an interleukin-31 receptor alpha antagonist that can also modulate each sort 2 and kind 17 helper T cells, he continued.
The OLYMPIA 2 part 2 trial randomly assigned 274 sufferers aged 18 years and older with prurigo nodularis to obtain nemolizumab (n = 183; imply age, 53.7 years; 61.7% girls) or placebo (n = 91; imply age, 50.8 years; 60.4% girls) each 4 weeks for 16 weeks to evaluate the efficacy of the drug.
A 4-point or better enchancment in Peak Pruritis Numerical Score Scale (PP-NRS) was reported in 56.3% of these within the therapy group in contrast with 20.9% of these within the placebo group.
IGA success was achieved by 37.7% of the therapy group and 11% of the placebo group.
Secondary endpoints, together with itch, sleep disturbance and pores and skin lesion enchancment at week 4, have been additionally statistically important within the therapy group. PP-NRS scores improved by at the least 4 factors in 41% of nemolizumab-treated sufferers at week 4, in contrast with 7.7% of these within the placebo group.
Sleep Disturbance Numerical Score Scale enhancements of at the least 4 factors have been reported by 37.2% at 4 weeks and 51.9% at 16 weeks within the therapy inhabitants, in contrast with 9.9% and 20.9% of the placebo group.
“Nemolizumab monotherapy, which is This fall weeks — month-to-month — was related to actually important enhancements in pruritus, pores and skin lesions and sleep disturbance at week 16, and these enhancements have been as early as week 4,” Kwatra mentioned.
“The outcomes of this research lengthen the efficacy and security findings from part 2 research of nemolizumab in sufferers with prurigo nodularis.”
